NasdaqHealth CareHealth Care EquipmentS&P SmallCap 600
$80.89
-2.60 (-3.11%)
Close of Nov 06, 2026 · end-of-day data
LMAT 8-K filings in 2025
Every material Form 8-K LeMaitre Vascular filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
LeMaitre Vascular reported preliminary, unaudited third-quarter 2025 results, with sales up 11% to $61.0 million and GAAP diluted EPS up 54% to $0.75. The results include a non-recurring $3.4 million Employee Retention Tax Credit benefit, and excluding it, adjusted diluted EPS was $0.62, up 27%. Management said it increased its bottom-line guidance, with full-year 2025 GAAP diluted EPS now expected at $2.48 to $2.53.
Q3 2025 net sales $61.0 million, up 11% (12% organic); GAAP diluted EPS $0.75, up 54%
Adjusted diluted EPS $0.62, up 27%, excluding the Employee Retention Tax Credit benefit
Full-year 2025 sales guidance $247 million to $249 million; Q4 2025 sales guidance $61.8 million to $63.8 million
Quarterly dividend of $0.20 per share, payable December 4, 2025, to holders of record on November 20, 2025
LeMaitre Vascular reported preliminary second-quarter 2025 results, with net sales of $64.2 million, up 15%, and diluted earnings per share of $0.60, up 16%. The company raised its full-year 2025 sales and earnings guidance, now projecting sales of $248 million to $254 million and diluted EPS of $2.23 to $2.37. The results are preliminary and unaudited.
Q2 2025 gross margin was 70.0%, up from 68.9% a year earlier, and operating income was $16.1 million, up 12%.
Full-year 2025 guidance: sales of $248 million to $254 million and EPS of $2.23 to $2.37.
Q3 2025 guidance: sales of $61.2 million to $63.2 million and EPS of $0.54 to $0.59.
Board approved a $0.20 per share quarterly dividend, payable September 4, 2025, to holders of record on August 21, 2025.
LeMaitre Vascular reported first-quarter 2025 net sales of $59.9 million, up 12% from a year earlier, and diluted earnings per share of $0.48, up from $0.44. The company raised its full-year 2025 sales guidance to $242 million to $249 million, from a prior $239 million, which gives shareholders a higher revenue outlook.
Q1 2025 net sales $59.9 million, up 12% (13% organic); gross margin 69.2%, up 60 basis points
Diluted EPS $0.48 vs. $0.44 a year earlier; income from operations $12.6 million, up 6%
Full-year 2025 sales guidance $242 million to $249 million, up from prior $239 million; Q2 sales guidance $61.5 million to $63.5 million
Quarterly dividend of $0.20 per share, payable May 29, 2025 to holders of record on May 15, 2025
LeMaitre Vascular reported preliminary fourth-quarter 2024 results, with net sales of $55.7 million, up 14% from a year earlier, and diluted EPS of $0.49 versus $0.38. The company also gave 2025 guidance of $235.4 million to $242.8 million in sales and $2.15 to $2.32 in EPS, and raised its quarterly dividend 25% to $0.20 per share. Sales and earnings growth, plus the dividend increase and a share repurchase authorization of up to $75.0 million, are the main items for shareholders.
Q4 2024 net income was $11.2 million, versus $8.5 million in Q4 2023; operating income was $12.9 million, up 26%.
Gross margin was 69.3%, up from 68.1% in Q4 2023.
2025 full-year sales guidance is $235.4 million to $242.8 million, compared with 2024 sales of $219.9 million.
The quarterly dividend rises to $0.20 per share, payable March 27, 2025; the board authorized up to $75.0 million in buybacks through February 17, 2026.
LeMaitre Vascular agreed on February 7, 2025 to appoint Dorian LeBlanc as Chief Financial Officer and principal financial officer, effective March 10, 2025. LeBlanc most recently served as CFO of LumiraDx Limited, and later as its Chief Operating Officer, and the filing describes his offer letter terms, including base salary, bonus target, equity awards and severance.
Dorian LeBlanc agreed to terms on February 7, 2025 and takes over as CFO effective March 10, 2025.
Starting annual base salary of $565,000, with a discretionary bonus target of $225,000 and an annual equity award of $375,000 vesting over four years.
One-time restricted stock unit award valued at $100,000, vesting over four years.
If terminated without cause on or before March 10, 2028, severance is $100,000; after that date, it is the greater of two weeks of base salary per full year of service or $225,000.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every LeMaitre Vascular filing is on SEC EDGAR ↗. 8-K briefs of other companies →